Litwin M, Boguszewska-Baczkowska A, Jelonek A
Oddziału Dializoterapii i Transpalntacji Nerek Centrum Zdrowia Dziecka.
Pol Tyg Lek. 1994;49(6-7):135-6.
Human recombinant erythropoietin has been administered to 6 children with uremic anaemia in the course of end stage renal disease, treated with CAPD. The drug has been injected subcutaneously in the dose of 2,000 U twice a week, until hematocrit and hemoglobin values equivalent to 30% and 9-10 g/dL have been achieved. A decrease in cytotoxic antibodies titre has been noted during a 6-month follow-up. No serious adverse reactions have been seen.
已对6名患有终末期肾病尿毒症贫血且接受持续性非卧床腹膜透析（CAPD）治疗的儿童使用了人重组促红细胞生成素。该药物以每周两次、每次2000单位的剂量皮下注射，直至血细胞比容和血红蛋白值分别达到30%和9 - 10 g/dL。在6个月的随访期间，观察到细胞毒性抗体滴度有所下降。未发现严重不良反应。
